T cell fraction impacts oncologic outcomes in human papillomavirus associated oropharyngeal squamous cell carcinoma
2020
Abstract Background We investigated T cell clonality (TCC) and T cell fraction (TCF) in human papilloma virus associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC) progressors [cases] vs. non-progressors [controls]. Methods This nested case-control study included patients undergoing intent-to-cure surgery ± adjuvant therapy from 6/1/2007–10/3/2016. Patients experiencing local/regional/distant disease (progressors), and a consecutive sample of non-progressors were matched (2 controls: 1 case) on tumor subsite, T-stage and number of metastatic lymph nodes. We performed imunosequencing of the CDR3 regions of human TCRβ chains. Results 34 progressors and 65 non-progressors were included. There was no statistically significant difference in baseline TCF (range: 0.039–1.084) and TCC (range: 0.007–0.240) (p > 0.05). Female sex was associated with higher TCF (p = 0.03), while extranodal extension (ENE) was associated with lower TCF (p = 0.01). There was a positive correlation between tumor size and clonality (R = 0.34, p Conclusions In patients with HPV(+)OPSCC, TCF was higher in female patients and those without ENE, suggesting differential immune responses. Lower TCF was significantly and independently associated with disease progression. Better ACE-27 scores appear to predict improved oncologic control.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
46
References
4
Citations
NaN
KQI